3
ALL3
Bioprojet PharmaYear
3
ALL1
20241
20231
2021DEALS // DEV.
3
ALL1
Deals2
DevelopmentsCountry
3
ALL3
FRANCE3
ALL1
Harmony Biosciences2
Not ApplicableTherapeutic Area
3
ALL3
SleepStudy Phase
3
ALL2
Approved1
PreclinicalDeal Type
1
ALL1
Licensing AgreementProduct Type
3
ALL3
Small moleculeDosage Form
2
ALL1
Tablet1
Tablet, Film CoatedLead Product
3
ALL2
Pitolisant Hydrochloride1
TPM-1116Target
0
ALLLead Product(s) : TPM-1116
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : Harmony Biosciences
Deal Size : $393.0 million
Deal Type : Licensing Agreement
Harmony Enters Agreement to Develop Oral Orexin-2 Agonist TPM-1116
Details : Through the Licensing Agreement, Bioprojet will develop, manufacture, and commercialize TPM-1116, a selective oral orexin-2 receptor agonist for narcolepsy and other sleep/wake disorders.
Brand Name : TPM-1116
Molecule Type : Small molecule
Upfront Cash : $25.5 million
April 11, 2024
Lead Product(s) : TPM-1116
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : Harmony Biosciences
Deal Size : $393.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Wakix (pitolisant) enhances the activity of histaminergic neurons and promotes wakefulness by blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse.
Brand Name : Wakix
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2023
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bioprojet: European Marketing Authorisation for OZAWADE™
Details : Ozawade (pitolisant hydrochloride) enhances the activity of histaminergic neurons, promotes wakefulness by blocking H3 autoreceptors and increases the levels of histamine transmitters at the synapse, and is used for Prader-Willi Syndrome.
Brand Name : Ozawade
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 03, 2021
Lead Product(s) : Pitolisant Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?